Alcohol Abuse Clinical Trial
— DEPREVOfficial title:
Multifactorial Analysis of the Influence of Alcohol Marketing Stimuli Among Young Adults on the Perception of the Risks of Alcohol and According to the Types of Uses and Individual Vulnerabilities
Verified date | July 2020 |
Source | University Hospital, Brest |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Alcohol use is the second leading cause of preventable death after smoking. The Evin law was
built in 1991 with the goal of reducing exposure to alcohol marketing among the youngest. But
this law is currently extremely weakened, and in a press release of February 26, 2018, the
French Society of Alcoology is alarmed by these developments.
Studies focusing on the impact of alcohol marketing focus largely on young adolescents, and
the links between exposure to marketing and the initiation of alcohol. But beyond these
links, there has been little work on the impact of alcohol marketing in vulnerable subjects
with regular alcohol consumption. Consumption of alcohol is one of the first causes of
hospitalization in France (Paille and Reynaud, 2015), the damage is often restricted to
notions of dependency risks, but they can appear as soon as consumptions of 1 US / d (Guerin
and Laplanche, 2013) and they mainly concern 45-64 year olds. To our knowledge, there are no
studies on the impact of alcohol marketing conducted on regular alcohol users, depending on
how they use alcohol (use, or use disorders). mild, moderate or severe) in patients enrolled
in primary care and specialized addiction care.
Status | Terminated |
Enrollment | 23 |
Est. completion date | February 25, 2020 |
Est. primary completion date | February 25, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Patients aged 18 to 45 years with moderate or severe alcohol use disorders - Followed in addiction at Brest CHRU Exclusion Criteria: - Major from 18 to 45 years - Current consumption of alcohol (multi-monthly) - Follow-up in primary care or addictology in Brest |
Country | Name | City | State |
---|---|---|---|
France | CHRU de Brest | Brest |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Brest | Ecole des Hautes Etudes en Santé Publique |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Alcohol craving | Evaluation of alcohol craving, evaluated by a visual analogue scale from 0 to 100. It is in the form of a straight line of 100 mm. In one ends is indicated: absence of pain, to the other: unbearable pain. The patient places a marks between these two ends depending on the intensity of his pain at a given time. In practice, it is a small plastic strip provided, on a face of a cursor mobilized by the patient, on the other with millimeter graduations read by the caregiver. | 1 day | |
Secondary | Level of anxiety | Assessment of the level of anxiety felt before and after the interview evaluated by a visual analogue scale from 0 to 100 | 1 day | |
Secondary | Perceived risks | Evaluation of perceived risks related to stimuli by individual interviews following the presentation of advertising images. It is not a scale but in interview where feelings are raised. No score. | 1 day | |
Secondary | Sensitivity to stimuli | Assessment of sensitivity to stimuli presented | 1 day | |
Secondary | Attractiveness of stimuli | Evaluation of the attractiveness of stimuli by individual interviews following the presentation of advertising images. It is not a scale but in interview where feelings are raised. No score. | 1 day | |
Secondary | Alcohol consumed | Evaluation of the categories of alcohol consumed | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03165942 -
Neuroendocrine Response to Oral Alcohol Administration
|
Phase 1 | |
Recruiting |
NCT05343039 -
Technology Enhanced Adolescent Mental Health (TEAM)
|
N/A | |
Active, not recruiting |
NCT04070521 -
EEG Monitoring in the Emergency Department
|
||
Completed |
NCT03169244 -
Buproprion for Binge Drinking
|
Phase 2 | |
Recruiting |
NCT05246202 -
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
|
N/A | |
Completed |
NCT05036499 -
PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain
|
N/A | |
Recruiting |
NCT04368416 -
Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
|
||
Not yet recruiting |
NCT04557631 -
Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol
|
||
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02448134 -
A Community-Based Strategy for Preventing Underage Drinking
|
N/A | |
Completed |
NCT02681406 -
Smartphone Based Continuing Care for Alcohol
|
N/A | |
Withdrawn |
NCT01796158 -
Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use
|
N/A | |
Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Withdrawn |
NCT01511679 -
Brain-imaging and Adolescent Neuroscience Consortium
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Withdrawn |
NCT01275391 -
cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Completed |
NCT00907309 -
Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use
|
Phase 1/Phase 2 |